Total submissions: 14
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Pediatric Genomic Medicine, |
RCV000224858 | SCV000280889 | pathogenic | not provided | 2014-12-18 | criteria provided, single submitter | clinical testing | |
Centre for Translational Omics - |
RCV000005608 | SCV000778576 | likely pathogenic | Hypoparathyroidism-retardation-dysmorphism syndrome | 2018-03-16 | criteria provided, single submitter | clinical testing | |
Department Of Genetics, |
RCV000005608 | SCV000891681 | pathogenic | Hypoparathyroidism-retardation-dysmorphism syndrome | 2017-12-30 | criteria provided, single submitter | clinical testing | |
Pathology and Clinical Laboratory Medicine, |
RCV000005608 | SCV000996294 | pathogenic | Hypoparathyroidism-retardation-dysmorphism syndrome | criteria provided, single submitter | clinical testing | ||
Gene |
RCV000224858 | SCV001820079 | pathogenic | not provided | 2024-08-14 | criteria provided, single submitter | clinical testing | In-frame deletion of 4 amino acids in a non-repeat region; In silico analysis supports a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 30080992, 29620724, 20152369, 26336027, 25097779, 30049826, 30638765, 26231322, 31589614, 36258138, 34374989, 35935360, 12389028) |
Revvity Omics, |
RCV000224858 | SCV002018933 | pathogenic | not provided | 2022-01-18 | criteria provided, single submitter | clinical testing | |
Centogene AG - |
RCV000005608 | SCV002028329 | pathogenic | Hypoparathyroidism-retardation-dysmorphism syndrome | 2021-07-20 | criteria provided, single submitter | clinical testing | |
3billion, |
RCV000005608 | SCV002521836 | pathogenic | Hypoparathyroidism-retardation-dysmorphism syndrome | 2022-05-22 | criteria provided, single submitter | clinical testing | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.001%). Inframe deletion located in a nonrepeat region: predicted to change the length of the protein and disrupt normal protein function. Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID:12389028). The variant has been observed in multiple (>3) similarly affected unrelated individuals (PMID:12389028, 20152369, 25097779, 26231322, 26336027, 30080992, 30638765). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. |
Labcorp Genetics |
RCV000224858 | SCV003524137 | pathogenic | not provided | 2023-01-13 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 5290). This variant has been observed in individuals with hypoparathyroidism-retardation-dysmorphism syndrome (PMID: 12389028, 20152369, 26231322, 30080992). It is commonly reported in individuals of Middle Eastern ancestry (PMID: 12389028, 30080992). This variant is present in population databases (rs767004810, gnomAD 0.006%). This variant, c.155_166del, results in the deletion of 4 amino acid(s) of the TBCE protein (p.Ser52_Gly55del), but otherwise preserves the integrity of the reading frame. |
Genomic Medicine Center of Excellence, |
RCV003989279 | SCV004805967 | pathogenic | Encephalopathy, progressive, with amyotrophy and optic atrophy | 2024-03-25 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000005608 | SCV000025790 | pathogenic | Hypoparathyroidism-retardation-dysmorphism syndrome | 2002-11-01 | no assertion criteria provided | literature only | |
OMIM | RCV000191990 | SCV000246253 | pathogenic | Autosomal recessive Kenny-Caffey syndrome | 2002-11-01 | no assertion criteria provided | literature only | |
Biochemical Molecular Genetic Laboratory, |
RCV000005608 | SCV001190740 | pathogenic | Hypoparathyroidism-retardation-dysmorphism syndrome | 2020-02-05 | no assertion criteria provided | clinical testing | |
Clinical Laboratory Sciences Program |
RCV000005608 | SCV003927852 | pathogenic | Hypoparathyroidism-retardation-dysmorphism syndrome | 2023-04-01 | no assertion criteria provided | clinical testing |